TOTAL: $368.92M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised ($M)*

Investors; Placement Agents; Details (Date)@

AltaRex Corp. (Canada; TSE:AXO)

Warrant exercise

5.687 shares

C$5.4 (US$3.66)

AltaRex received C$5.4M (US$3.66M) from the exercise of special warrants sold 2/29/00 into common shares (4/20)

Aphton Corp. (APHT)

Private placement of common stock

0.49 shares

$16.22

Aphton sold 0.49M shares of common stock at $33 per share to raise $16.22M; Morgan Stanley Dean Witter and Gruntal & Co. assisted in the placement (4/12)

Aronex Pharmaceuticals Inc. (ARNX)

Private placement of units

81 units

$8.1

Aronex sold units for $100,000 each; each unit consists of 36,364 shares of common stock and a five-year warrant to purchase 12,121 shares of common stock at $3 per share; Paramount Capital Inc. acted as financial adviser (4/18)

Aviron (AVIR)

Private placement of common stock

0.14 shares

$4

Under previously filed registration form S-3, Aviron sold 0.14M shares to Acqua Wellington Asset Management LLC at $27.74 per share, raising gross proceeds of $4M; Aviron may sell up to $48M in shares to Acqua over 12 months (4/13)

BioChem Pharma Inc. (Canada; BCHE)

Product development investment to be repaid with royalties

­

C$80 (US$55.18)

BioChem entered a partnership agreement with the Canadian government through Technology Partnerships Canada, under which the government will invest C$80M (US$55.18M) in BioChem's recombinant protein vaccines program and will be repaid with royalties on commercialized products (4/3)

Biosyntech Inc. (Canada: OTC BB:BSYI)

Private placement of units

1.8 units

$6.3

Biosyntech sold 1.8M units at $3.50 per unit for total proceeds of $6.3M; each unit consists of one share of common stock and one warrant to buy a common share at $4.50 by 3/31/01 (4/20)

Calypte Biomedical Corp. (CALY)

Private placement of common stock

4.1 shares

$8.4

Calypte sold 4.1M shares at $2.05 per share for proceeds of $8.4M; half of the financing was provided by Trilobite Lakes Corp., a wholly owned subsidiary of Claneil Enterprises Inc. (4/13)

Cytoclonal Pharmaceutics Inc. (CYPH)

Warrant redemption

­

$25.7

Cytoclonal completed the call for redemption of publicly traded Class D warrants; about 65% of the warrants (2.4M) were exercised, allowing holders to buy one share of common stock at $8.75 for each warrant held (4/17)

Endorex Corp. (AMEX:DOR)

Private placement of common stock and warrants

1.81 shares, warrants for 0.455 shares

$8.6

Endorex raised $8.6M through a private placement of 1.81M shares priced at $4.75 per share to domestic and foreign institutional investors; investors also received warrants to buy 0.455M common shares at $5.91 per share; Paramount Capital Inc. acted as financial adviser (4/13)

Epoch Pharmaceuticals Inc. (OTC BB: EPPH)

Warrant redemption

3.795 shares

$9.5

Epoch raised $9.5M through the exercise of warrants for 3.795M shares of common stock at $2.50 per share (4/10)

Helix BioPharma Corp. (Canada; TSE:HBP)

Private placement of units

3 units

C$10 (US$6.89)

Helix placed 3M units at C$3.33 (US$2.29) per unit with a private European investment company, raising C$10M (US$6.89M); the units consist of 3M shares plus warrants to purchase 1.5M shares at C$6.66 (US$4.59) per share for one year and warrants to purchase 1.5M shares at C$10 (US$6.89M) for two years (4/5)

Hemosol Inc. (Canada; TSE:HML)

Bought deal financing

1.06 shares

C$20.1 (US$13.84)

Hemosol sold 1.06M shares at $19 each in a bought deal financing with a syndicate of underwriters led by Yorkton Securities Inc. (4/5)

Integra LifeSciences Corp. (IART)

Private placement of convertible preferred stock and warrants

0.054 preferred shares, warrants for 0.3 shares

$5.4

Integra raised $5.4M from investment affiliates of Soros Private Equity Partners LLC, which bought 54,000 shares of Series C convertible preferred stock that are convertible into 0.6M shares of common stock, plus warrants to purchase an additional 0.3M shares at $9 per share (4/6)

Matritech Inc. (NMPS)

Warrant exercise

1.3 shares

$2.8

Matritech raised $2.8M through the exercise of three separate stock purchase warrants in 1Q:00 for 1.3M shares of stock; to date, all but 88,137 warrants have been exercised (4/10)

NeoRx Corp. (NERX)

Private placement of common stock

1.73 shares

$19

NeoRx sold 1.73M shares of common stock at $11 each to institutional investors for gross proceeds of $19M; placement agents were Adams, Harkness & Hill, and Roth Capital Partners Inc. (4/24)

NeoTherapeutics Inc. (NEOT)

Private placement of subordinated convertible debentures

­

$10

NeoTherapeutics placed $10M worth of 5% subordinated convertible debentures due 4/6/05; subject to certain conditions, investors agreed to fund two future tranches of up to $10M each and redeemable warrants to purchase up to 4M shares of common stock over a two-year period exercisable at $33.75 per share (for a potential total of $69M); debentures are convertible into common stock at $20.25 per share for the first 90 days, and at the lesser of $20.25 or 101% of the market price thereafter (4/10)

Neurobiological Technologies Inc. (OTC BB:NTII)

Private placement of common stock

1.19 shares

$6.36

Neurobiological Technologies sold 1.19M shares at $5.30 per share for proceeds of $6.36M; investors included Capital Research Co. and Gotham Capital Management; AmeriCal Securities Inc. acted as placement agent (4/19)

Novopharm Biotech Inc. (Canada; TSE:NVO)

Private placement of units

6.85 units

C$5 (US$3.45)

Dan Family Holdings Ltd. will purchase 6.85M units at C$0.73 (US$0.50) per unit; each unit consists of one common share and one-half common share purchase warrant; each full warrant may be exercised at C$0.73 per share (US$0.50) during the first year and $1.50 the second year; deal also includes a second tranche in the form of a non-interest bearing facility for C$7M (US$4.83M), from which Novopharm may draw in C$1M (US$0.69M) increments after 8/31/00 (4/3)

NPS Pharmaceuticals Inc. (NPSP)

Private placement of common stock

3.9 shares

$46.8

NPS sold an aggregate of 3.9M shares of common stock at $12 each for gross proceeds of $46.8M ($43.5M net); Prudential Vector Healthcare Group served as placement agent (4/24)

Oxis International Inc. (OXIS)

Private placement of units

ND

$6.25

Oxis raised $1.45M in second tranche of a units placement; units consist of one share of common stock and warrants to purchase two shares of common stock; units in the second tranche were priced at $3.94; one share covered by the warrants may be purchased at $4.92, or 125% of unit price, and the second may be purchased at $5.91, or 150% of the unit price (4/20)

Procyon BioPharma Inc. (Canada; VSE:PBP)

Private placement of special warrants

7.79 warrants

C$20.4 (US$13.94)

Procyon offered 7.79M warrants at C$2.62 (US$1.79) each; each warrant will be exercisable, at no additional cost, into one common share and one-half of one common share purchase warrant; each whole warrant entitles holder to purchase a common share for C$3.93 (US$0.68) within two years; Research Capital Corp. led the financing (4/11)

SangStat Medical Corp. (SANG)

Line of credit

­

$30

SangStat reached an agreement with Finova Capital Corp. for a $30M credit line at the prime rate of interest plus 0.75% (4/24)

Sepragen Corp. (OTC BB: SPGNA)

Private placement of common stock

3.445 shares

$2.58

Sepragen sold 3.445M shares of common stock at $0.75 per share for gross proceeds of $2.58M; investors include Koyah Leverage Partners LP and Koyah Partners (both managed by ICM Asset Management) and Special Situations Private Equity Fund LP; Crown Point Securities LLC served as placement agent (4/5)

Siga Technologies Inc. (SIGA)

Private placement of common stock and warrants

0.6M shares and warrants

$3

Siga completed a $3M private placement consisting of 0.6M shares of common stock and attached warrants (4/7)

Synthetic Blood International (OTC BB:SYBD)

Private placement

ND

$2

Synthetic Blood received first installment of $5.5M financing commitment from offshore investors (4/3)

Theratechnologies (Canada; TSE:TH)

Private placement of warrants

­

C$10.8 (US$7.35)

Theratechnologies placed C$10.8M (US$7.35) worth of warrants with an institutional investor entitling the holder to acquire, without additional payment, 1.2M common shares of Theratechnologies' new spin-off Ecopia BioSciences within 18 months of the listing date of Ecopia's shares on a recognized market, or 0.54M shares of Theratechnologies if Ecopia is not listed by 5/5/04 (4/26)

Trega Biosciences Inc. (TRGA)

Private placement of common stock

3.7 shares

$11

Trega sold 3.7M shares of common stock for gross proceeds of $11M (4/5)

Trinity Biotech (Ireland; TRIBY)

Private placement of common stock

4 shares

$13.4

Trinity placed 4M shares at $3.35 per share for gross proceeds of $13.4M; Goodbody Stockbrokers, a subsidiary of AIB Bank in Ireland, served as placement agent (4/5)

Valentis Inc. (VLTS)

Private

1.915 shares placement of common stock

$19.2

Valentis sold 1.915M shares of common stock for $10 each to raise $19.2M; investors included the State of Wisconsin Investment Board, BayStar Capital and Merlin BioMed Asset Management in the U.S.; Framlington Asset Management, Park Place Capital and the Finsbury Trust in the UK; Compania Financiera Internacional and BSI-AG in Switzerland; and Banca Intermobiliare di Invetimenti in Italy (4/14)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Non-U.S. currencies converted at the exchange rate on the date of the announcement.

@ Dates listed are the dates of press releases, and are not necessarily the dates on which stated events took place.

ASX = Australian Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange; OTC BB = Over The Counter Bulletin Board

No Comments